Cargando…
Umbilical Cord PRP vs. Autologous PRP for the Treatment of Hip Osteoarthritis
Umbilical cord platelet-rich plasma (C-PRP) has more growth factors and anti-inflammatory molecules compared with autologous PRP (A-PRP) derived from peripheral blood. The aim of this study was to compare intra-articular C-PRP or A-PRP injections in terms of safety and clinical efficacy for the trea...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369463/ https://www.ncbi.nlm.nih.gov/pubmed/35956121 http://dx.doi.org/10.3390/jcm11154505 |
_version_ | 1784766466493513728 |
---|---|
author | Mazzotta, Alessandro Pennello, Enrico Stagni, Cesare Del Piccolo, Nicolandrea Boffa, Angelo Cenacchi, Annarita Buzzi, Marina Filardo, Giuseppe Dallari, Dante |
author_facet | Mazzotta, Alessandro Pennello, Enrico Stagni, Cesare Del Piccolo, Nicolandrea Boffa, Angelo Cenacchi, Annarita Buzzi, Marina Filardo, Giuseppe Dallari, Dante |
author_sort | Mazzotta, Alessandro |
collection | PubMed |
description | Umbilical cord platelet-rich plasma (C-PRP) has more growth factors and anti-inflammatory molecules compared with autologous PRP (A-PRP) derived from peripheral blood. The aim of this study was to compare intra-articular C-PRP or A-PRP injections in terms of safety and clinical efficacy for the treatment of patients with hip osteoarthritis (OA). This study investigated the results of 100 patients with hip OA treated with three weekly ultrasound-guided injections of either C-PRP or A-PRP. Clinical evaluations were performed before the treatment and after two, six, and twelve months with the HHS, WOMAC, and VAS scores. No major adverse events were recorded. Overall, the improvement was limited with both treatments. Significant improvements in VAS (p = 0.031) and HHS (p = 0.011) were documented at two months for C-PRP. Patients with a low OA grade (Tonnis 1-2) showed a significantly higher HHS improvement with C-PRP than A-PRP at twelve months (p = 0.049). C-PRP injections are safe but offered only a short-term clinical improvement. The comparative analysis did not demonstrate benefits compared with A-PRP in the overall population, but the results are influenced by OA severity, with C-PRP showing more benefits when advanced OA cases were excluded. Further studies are needed to confirm the most suitable indications and potential of this biological injective approach. |
format | Online Article Text |
id | pubmed-9369463 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93694632022-08-12 Umbilical Cord PRP vs. Autologous PRP for the Treatment of Hip Osteoarthritis Mazzotta, Alessandro Pennello, Enrico Stagni, Cesare Del Piccolo, Nicolandrea Boffa, Angelo Cenacchi, Annarita Buzzi, Marina Filardo, Giuseppe Dallari, Dante J Clin Med Article Umbilical cord platelet-rich plasma (C-PRP) has more growth factors and anti-inflammatory molecules compared with autologous PRP (A-PRP) derived from peripheral blood. The aim of this study was to compare intra-articular C-PRP or A-PRP injections in terms of safety and clinical efficacy for the treatment of patients with hip osteoarthritis (OA). This study investigated the results of 100 patients with hip OA treated with three weekly ultrasound-guided injections of either C-PRP or A-PRP. Clinical evaluations were performed before the treatment and after two, six, and twelve months with the HHS, WOMAC, and VAS scores. No major adverse events were recorded. Overall, the improvement was limited with both treatments. Significant improvements in VAS (p = 0.031) and HHS (p = 0.011) were documented at two months for C-PRP. Patients with a low OA grade (Tonnis 1-2) showed a significantly higher HHS improvement with C-PRP than A-PRP at twelve months (p = 0.049). C-PRP injections are safe but offered only a short-term clinical improvement. The comparative analysis did not demonstrate benefits compared with A-PRP in the overall population, but the results are influenced by OA severity, with C-PRP showing more benefits when advanced OA cases were excluded. Further studies are needed to confirm the most suitable indications and potential of this biological injective approach. MDPI 2022-08-02 /pmc/articles/PMC9369463/ /pubmed/35956121 http://dx.doi.org/10.3390/jcm11154505 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Mazzotta, Alessandro Pennello, Enrico Stagni, Cesare Del Piccolo, Nicolandrea Boffa, Angelo Cenacchi, Annarita Buzzi, Marina Filardo, Giuseppe Dallari, Dante Umbilical Cord PRP vs. Autologous PRP for the Treatment of Hip Osteoarthritis |
title | Umbilical Cord PRP vs. Autologous PRP for the Treatment of Hip Osteoarthritis |
title_full | Umbilical Cord PRP vs. Autologous PRP for the Treatment of Hip Osteoarthritis |
title_fullStr | Umbilical Cord PRP vs. Autologous PRP for the Treatment of Hip Osteoarthritis |
title_full_unstemmed | Umbilical Cord PRP vs. Autologous PRP for the Treatment of Hip Osteoarthritis |
title_short | Umbilical Cord PRP vs. Autologous PRP for the Treatment of Hip Osteoarthritis |
title_sort | umbilical cord prp vs. autologous prp for the treatment of hip osteoarthritis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369463/ https://www.ncbi.nlm.nih.gov/pubmed/35956121 http://dx.doi.org/10.3390/jcm11154505 |
work_keys_str_mv | AT mazzottaalessandro umbilicalcordprpvsautologousprpforthetreatmentofhiposteoarthritis AT pennelloenrico umbilicalcordprpvsautologousprpforthetreatmentofhiposteoarthritis AT stagnicesare umbilicalcordprpvsautologousprpforthetreatmentofhiposteoarthritis AT delpiccolonicolandrea umbilicalcordprpvsautologousprpforthetreatmentofhiposteoarthritis AT boffaangelo umbilicalcordprpvsautologousprpforthetreatmentofhiposteoarthritis AT cenacchiannarita umbilicalcordprpvsautologousprpforthetreatmentofhiposteoarthritis AT buzzimarina umbilicalcordprpvsautologousprpforthetreatmentofhiposteoarthritis AT filardogiuseppe umbilicalcordprpvsautologousprpforthetreatmentofhiposteoarthritis AT dallaridante umbilicalcordprpvsautologousprpforthetreatmentofhiposteoarthritis |